港股異動 | 新秀麗(1910.HK)連續第3日反彈 機構唱好+股東增持
格隆匯12月23日丨新秀麗(1910.HK)續升超4%,3日累計反彈逾10%。報15.04港元,總市值216億港元。大摩預期新秀麗的股價在未來30日內有70%至80%機率會上升。該行指出,在確診個案增加及新變種病毒株Omicron的不明朗因素下,新秀麗股價一直疲軟,認為風險回報水平吸引,相信現時為入市好時機。該行看好公司前景,給予目標價19.7港元,評級增持。此外,近期公司獲股東Hermes Investment Management Ltd增持約153.86萬股,總金額約為2481.81萬港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.